CAS 115575-11-6: Liarozole

Liarozole

Liarozole dihydrochloride inhibits CYP450, estrogen, androgen synthesis; an oral drug for prostate cancer/skin disorders.

Liarozole is an imidazole derivative that functions as a non-specific inhibitor of cytochrome P450-dependent retinoic acid metabolism. It primarily acts by inhibiting the cytochrome P450 enzyme family, particularly affecting the 4-hydroxylation process. This inhibition increases the local concentration of retinoic acid in tissues, which can lead to a modulation of transcriptional activity by retinoic acid receptors and ultimately influence cellular proliferation and differentiation. Liarozole has been investigated for its potential applications in oncology, particularly for the treatment of hormone-refractory prostate cancer and certain skin disorders. Its ability to elevate retinoic acid levels provides a useful mechanism to manipulate cellular processes disrupted in cancer and dermatological conditions. While the exact therapeutic pathways are still under exploration, liarozole's capacity to interfere with steroid metabolism further broadens its potential clinical utility. Researchers and clinicians remain interested in its applications for diseases characterized by dysregulated retinoid homeostasis.